Send me real-time posts from this site at my email

Kronos Bio (KRON) Receives a Buy from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Kronos Bio (KRONResearch Report), with a price target of $35.00. The company's shares closed last Monday at $17.14, close to its 52-week low of $17.10.

According to, Burns ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.9% and a 22.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kronos Bio with a $35.00 average price target.

See today’s analyst top recommended stocks >> Based on Kronos Bio's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $29.06 million. In comparison, last year the company had a GAAP net loss of $8.58 million. Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRON in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Read More on KRON:

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue